At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 19,102 enrolled
Drug / intervention
Ivabradine +1 moredrug
Likely dose
Ivabradine 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart Failure. A Randomised Double-blind Placebo-controlled International Multicenter Study. Study Assessing the Morbi-mortality Benefits of the If Inhibitor Ivabradine in Patients With Coronary Artery Disease
Institut de Recherches Internationales Servier·interventional·Posted May 18, 2015·Updated Jul 26, 2024
In Brief
A Phase 3 clinical trial evaluating Ivabradine and Placebo for Coronary Artery Disease. Completed, enrolled 19,102 participants across 2 sites in 2 countries.
Detailed Summary
The purpose of this study is to evaluate the effect of ivabradine on cardiovascular events in patients with coronary artery disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesItaly, United Kingdom
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2009
Primary CompletionJan 2014
First PostedMay 2015
TodayJul 2026
First PostedMay 18, 2015
Enrollment StartSep 1, 2009
Primary CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 11.1 years ago
Interventions
Ivabradinedrug
5 mg, 7.5 mg or 10 mg tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 48 months.
Placebodrug
Matching placebo tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 48 months.